Summary
Vijay Pande, formerly of a16z, discusses his new, smaller AI-native venture capital firm, VZVC, and his views on the shift of biology from a discovery science to an engineering one. He also addresses the high cost of clinical trials and the potential of open datasets to transform medicine through AI.